HIA
TVTX icon

Harbor Investment Advisory’s Travere Therapeutics TVTX Stock Holding History

Harbor Investment Advisory’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,249
Closed -$49.9K – 1342
2023
Q2 		$49.9K Hold
3,249
– – 0.01% 714
2023
Q1 		$73.1K Hold
3,249
– – 0.01% 591
2022
Q4 		$68.3K Buy
3,249
+457
+16% +$9.68K 0.01% 594
2022
Q3 		$69K Sell
2,792
-351
-11% -$9.07K 0.01% 574
2022
Q2 		$76K Hold
3,143
– – 0.01% 571
2022
Q1 		$81K Sell
3,143
-281
-8% -$7.46K 0.01% 595
2021
Q4 		$106K Hold
3,424
– – 0.01% 521
2021
Q3 		$83K Hold
3,424
– – 0.01% 578
2021
Q2 		$50K Buy
3,424
+883
+35% +$17.4K 0.01% 706
2021
Q1 		$63K Buy
2,541
+57
+2% +$1.57K 0.01% 615
2020
Q4 		$68K Buy
2,484
+526
+27% +$12.3K 0.01% 551
2020
Q3 		$36K Buy
1,958
+974
+99% +$18.9K 0.01% 594
2020
Q2 		$20K Hold
984
– – ﹤0.01% 639
2020
Q1 		$14K Buy
+984
New +$14.8K ﹤0.01% 666

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Harbor Investment Advisory's TVTX Position: Q3 2023 in Review

Harbor Investment Advisory sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 3,249 shares — an estimated $49.9K sold.

Harbor Investment Advisory first reported a position in TVTX in Q1 2020 and held it in 14 quarters. The position peaked at $106K in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • Harbor Investment Advisory reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Harbor Investment Advisory sold 3,249 Travere Therapeutics shares in Q3 2023, an estimated $49.9K.
  • Harbor Investment Advisory first reported a position in Travere Therapeutics in Q1 2020 and held it in 14 quarters.
  • Harbor Investment Advisory's Travere Therapeutics position peaked at $106K in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Harbor Investment Advisory's 13F filing for Q3 2023, filed 13 Oct 2023.